Risk factors for diabetes mellitus and impaired glucose tolerance following allogeneic hematopoietic stem cell transplantation in pediatric patients with hematological malignancies

Hirabayashi, Kanae; Nakazawa, Yozo; Matsuura, Hiroki; Hara, Yosuke; Kurata, Tadao; Hirabayashi, Koichi; Saito, Shoji; Yoshikawa, Kentaro; Tanaka, Miyuki; Yanagisawa, Ryu; Sakashita, Kazuo; Koike, Kenichi

doi:10.1007/s12185-014-1536-8

Cited by 18 publications

(13 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, none of the patients were obese/overweight. 17 In another cohort of childhood-transplanted patients, 15% of 45 patients showed abnormal glucose tolerance but only 1 was obese. However, a waist/height ratio of 40.5 was associated with abnormal glucose tolerance in 85%, compared with 42% of patients with normal glucose tolerance, and 23% of controls.…”

Section: Transplant-related Factorsmentioning

confidence: 98%

See 1 more Smart Citation

How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT

Fuji

Rovó

Ohashi

et al. 2016

Bone Marrow Transplant

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients frequently develop glucose intolerance and post-transplant diabetes mellitus (PTDM). The clinical importance of PTDM and its detrimental impact on HSCT outcomes are underrecognized. After allo-HSCT, various mechanisms can contribute to the development of PTDM. Here we review information about hyperglycemia and PTDM after allo-HSCT as well as PTDM after solid organ transplantation and describe ways to manage hyperglycemia/PTDM after allogeneic HSCT. Taking into consideration a lack of well-established evidence in the field of allo-HSCT, more studies should be conducted in the future, which will require closer multidisciplinary collaboration between hematologists, endocrinologists and nutritionists.

show abstract

Section: Transplant-related Factorsmentioning

confidence: 98%

“…These findings were not confirmed by other studies, in which only age 46 years at the time of HSCT in a pediatric cohort was associated with increased risk of PTDM/impaired glucose tolerance. 17 …”

Section: Inflammationmentioning

confidence: 99%

How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT

Fuji

Rovó

Ohashi

et al. 2016

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…One group evaluates only patients with malignant hematologic (MaHe) condition and the other group for all other conditions. The MaHe group (Hoffmeister et al, 2004;Oudin et al, 2011;Hirabayashi et al, 2014;Oudin et al, 2015) has the pooled MD of 4.98, 95% CI1.85-13.42, I 2 =0% and the other studies with pooled MD of 5.55, 95% CI 2.02-15.25, I 2 =95.4% (Taskinen et al, 2000;Neville et al, 2006;Baker et al, 2007;Meacham et al, 2010;Armenian et al, 2012;Nakagawa et al, 2018;Shalitin et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

“…In addition, for the study designs, we categorized the studies into prospective, cross-sectional and retrospective studies and found the following pooled MD: 3.21, 95% CI 1.53-6.73, I 2 =71.3% for retrospective studies (Hoffmeister et al, 2004;Baker et al, 2007;Armenian et al, 2012;Hirabayashi et al, 2014;Shalitin et al, 2018) while for prospective study the pool MD was 12.75, 8.77-18.53, I 2 =16.3%, and 6.76, 95% CI 3.32-13.74, I 2 =0% for cross-sectional studies (Taskinen et al, 2000;Meacham et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

“…First, for age group, we categorized the studies to include only pediatric population and the other for adult patients. Pooled MD among adult group (Baker et al, 2007;Armenian et al, 2012) was 2.09, 95% CI 0.95-4.61, I 2 =71.7% while for the pediatric group (Taskinen et al, 2000;Hoffmeister et al, 2004;Neville et al, 2006;Oudin et al, 2011;Michael et al, 2013;Hirabayashi et al, 2014;Oudin et al, 2015;Nakagawa et al, 2018;Shalitin et al, 2018), the pooled MD was 8.43, 95% CI 5.51-12.91, cross-sectional study design has limitations to accurately diagnose DM/IGM after patients received TBI as the diagnosis is based on a single timeframe rather than a prolonged period of follow-up time in cohort studies. The association remained statistically significant after exclusion of two cross-sectional studies.…”

Section: See Details For Meta-analysis In S4 In Supplementary Materiamentioning

confidence: 98%

See 1 more Smart Citation

Total Body Irradiation and Risk of Diabetes Mellitus; A Meta-Analysis

Poonsombudlert

Limpruttidham

2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective:Hematopoietic stem cell transplant (HSCT) has recently emerged as a cure for previously “incurable” diseases and is being explored and attempted in many other fields including congenital and acquired non-malignant diseases. However, the long-term side effect associated with HSCT especially Total Body Irradiation (TBI) is still understudied. Therefore, we attempted to establish association between TBI and risk of developing Diabetes Mellitus (DM) or impaired glucose metabolism (IGM).Methods:We searched for titles of articles in MEDLINE (PubMed), EMBASE, and Cochrane library in August 2018 that evaluated the association between TBI in the setting of HSCT and DM or IGM. We conducted a random effect meta-analysis of 11 studies involving a total of 13,191 participants and reported the pooled MD (mean difference) for the development of DM/IGM after TBI as part of the conditioning regimen for HSCT.Results:We found a significant increase in the risk of developing DM/IGM after TBI is used as part of the conditioning regimen compared to other types of conditioning regimen with the pooled MD being 5.42, 95% Confidence Interval (CI) 2.51-11.71, I2=92.4%.Conclusion:TBI as a conditioning regimen in the setting of HSCT significantly increases the risk of developing DM/IGM. Therefore, we recommend close monitoring and screening for diabetes mellitus in patients who underwent TBI before HSCT.

show abstract

Cardiovascular risk factors

Doucette

Battiwalla

2021

Blood and Marrow Transplantation Long Term Management

View full text Add to dashboard Cite

Risk factors for diabetes mellitus and impaired glucose tolerance following allogeneic hematopoietic stem cell transplantation in pediatric patients with hematological malignancies

Cited by 18 publications

References 31 publications

How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT

How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT

Total Body Irradiation and Risk of Diabetes Mellitus; A Meta-Analysis

Cardiovascular risk factors

Contact Info

Product

Resources

About